<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: factors could", fill: "#e34234"},
{source: "3: factors could", target: "3: common stock", fill: "#e34234"},
{source: "3: common stock", target: "3: could lose", fill: "#e34234"},
{source: "3: could lose", target: "3: investment", fill: "#e34234"},
{source: "3: factors could", target: "11: may continue", fill: "#008000"},
{source: "11: may continue", target: "11: losses even", fill: "#008000"},
{source: "11: losses even", target: "11: generate revenues from", fill: "#008000"},
{source: "11: generate revenues from", target: "11: drug candidates", fill: "#008000"},
{source: "11: drug candidates", target: "11: technologies", fill: "#008000"},
{source: "11: may continue", target: "13: commercialize one", fill: "#f0e68c"},
{source: "13: commercialize one", target: "13: drug candidates", fill: "#f0e68c"},
{source: "13: drug candidates", target: "13: technologies", fill: "#f0e68c"},
{source: "13: technologies", target: "13: become profitable", fill: "#f0e68c"},
{source: "13: commercialize one", target: "14: profitability depends on", fill: "#fada5e"},
{source: "14: profitability depends on", target: "14: development efforts", fill: "#fada5e"},
{source: "14: development efforts", target: "14: regulatory approval", fill: "#fada5e"},
{source: "14: regulatory approval", target: "14: drug candidates successfully", fill: "#fada5e"},
{source: "14: drug candidates successfully", target: "14: drug candidates", fill: "#fada5e"},
{source: "14: drug candidates", target: "14: successfully", fill: "#fada5e"},
{source: "14: successfully", target: "14: postapproval regulatory", fill: "#fada5e"},
{source: "14: postapproval regulatory", target: "14: obligations", fill: "#fada5e"},
{source: "14: obligations", target: "14: commercialize", fill: "#fada5e"},
{source: "14: commercialize", target: "14: technologies", fill: "#fada5e"},
{source: "14: profitability depends on", target: "15: Risks Associated ", fill: "#c19a6b"},
{source: "15: Risks Associated ", target: "15: successfully", fill: "#c19a6b"},
{source: "15: successfully", target: "15: clinical trial programs", fill: "#c19a6b"},
{source: "15: clinical trial programs", target: "15: such clinical trials", fill: "#c19a6b"},
{source: "15: such clinical trials", target: "15: strategy will", fill: "#c19a6b"},
{source: "15: strategy will", target: "15: adversely affected", fill: "#c19a6b"},
{source: "15: Risks Associated ", target: "26: If the FDA ", fill: "#fadadd"},
{source: "26: If the FDA ", target: "26: Phase III ", fill: "#fadadd"},
{source: "26: Phase III ", target: "26: Phase IV ", fill: "#fadadd"},
{source: "26: Phase IV ", target: "26: clinical trial may yield", fill: "#fadadd"},
{source: "26: clinical trial may yield", target: "26: safety concerns which could", fill: "#fadadd"},
{source: "26: safety concerns which could", target: "26: such approval", fill: "#fadadd"},
{source: "26: such approval", target: "26: product from", fill: "#fadadd"},
{source: "26: If the FDA ", target: "77: contract with third parties", fill: "#69359c"},
{source: "77: contract with third parties", target: "77: manufacture", fill: "#69359c"},
{source: "77: manufacture", target: "77: product candidates", fill: "#69359c"},
{source: "77: product candidates", target: "77: assist us", fill: "#69359c"},
{source: "77: assist us", target: "77: regulatory approval", fill: "#69359c"},
{source: "77: regulatory approval", target: "77: commercializing", fill: "#69359c"},
{source: "77: commercializing", target: "77: technologies", fill: "#69359c"},
{source: "77: technologies", target: "77: drug products", fill: "#69359c"},
{source: "77: contract with third parties", target: "101: competitors", fill: "#0f4d92"},
{source: "101: competitors", target: "101: market products", fill: "#0f4d92"},
{source: "101: market products", target: "101: less expensive", fill: "#0f4d92"},
{source: "101: less expensive", target: "101: effective", fill: "#0f4d92"},
{source: "101: effective", target: "101: safer than", fill: "#0f4d92"},
{source: "101: safer than", target: "101: drug products", fill: "#0f4d92"},
{source: "101: drug products", target: "101: commercial opportunities may", fill: "#0f4d92"},
{source: "101: competitors", target: "START_HERE", fill: "#0f4d92"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mirati_Therapeutics">Mirati Therapeutics</a></td>
      <td>Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.\n\n\n== History ==\nMirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_design">Drug design</a></td>
      <td>Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Santaris_Pharma">Santaris Pharma</a></td>
      <td>Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dell_Technologies">Dell Technologies</a></td>
      <td>Dell Technologies Inc. is an American multinational technology company headquartered in Round Rock, Texas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">Food and Drug Administration</a></td>
      <td>The United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods &amp; feed and veterinary products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug">Drug</a></td>
      <td>The drum is a member of the percussion group of musical instruments. In the Hornbostel-Sachs classification system, it is a membranophone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Combination_drug">Combination drug</a></td>
      <td>A combination drug or a fixed-dose combination (FDC) is a medicine that includes two or more active ingredients combined in a single dosage form. Terms like "combination drug" or "combination drug product" can be common shorthand for a FDC product (since most combination drug products are currently FDCs), although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages (as opposed to customized polypharmacy via compounding).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_nomenclature">Drug nomenclature</a></td>
      <td>Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are the International Nonproprietary Names (INNs); and trade names, which are brand names.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Over-the-counter_drug">Over-the-counter drug</a></td>
      <td>Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription.  In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biopharmaceutical">Biopharmaceutical</a></td>
      <td>A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>KERYX BIOPHARMACEUTICALS INC      ITEM 1A  RISK FACTORS           You <font color="blue">should carefully</font> consider the <font color="blue">following risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>If any     of the following occurs, our business, <font color="blue">financial condition</font> or operating     results could be <font color="blue">materially harmed</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> cause the trading     price of our <font color="blue">common stock</font> to decline, and you <font color="blue">could lose</font> all or part of your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       We have a limited operating history and have incurred substantial operating     <font color="blue">losses since</font> our inception</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses</font> in the     future and <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>You should consider our prospects in     light of the risks and <font color="blue"><font color="blue"><font color="blue">difficult</font>ies</font> frequently encountered by early stage</font>     companies</td>
    </tr>
    <tr>
      <td>In  addition,  we have incurred operating <font color="blue">losses since</font> our     inception  and  expect  to  continue to incur operating losses for the     <font color="blue">foreseeable future</font> and <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005,     we had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra114dtta4 million</td>
    </tr>
    <tr>
      <td>As we expand     our research and <font color="blue"><font color="blue">development</font> efforts</font>, we <font color="blue">will incur increasing losses</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">may continue</font> to incur substantial operating <font color="blue">losses even</font> if we begin to     <font color="blue"><font color="blue">generate revenue</font>s from</font> our <font color="blue">drug <font color="blue">candidates</font></font> or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">yet <font color="blue">commercialize</font>d</font> any products or <font color="blue">technologies</font> and cannot be     sure we will ever be able to do so</td>
    </tr>
    <tr>
      <td>Even if we <font color="blue"><font color="blue">commercialize</font> one</font> or more of     our <font color="blue">drug <font color="blue">candidates</font></font> or <font color="blue">technologies</font>, we may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Our     ability to achieve <font color="blue">profitability depends on</font> a number of factors, including     our ability to complete our <font color="blue"><font color="blue">development</font> efforts</font>, obtain <font color="blue"><font color="blue">regulatory</font> approval</font>     for our <font color="blue">drug <font color="blue">candidates</font></font>, <font color="blue">successfully</font> complete any post-approval <font color="blue">regulatory</font>     <font color="blue">obligations</font>  and  <font color="blue">successfully</font>  <font color="blue">commercialize</font>  our <font color="blue">drug <font color="blue">candidates</font></font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with Our Product Development Efforts       If we are unable to <font color="blue">successfully</font> complete our <font color="blue">clinical trial programs</font>, or if     <font color="blue">such <font color="blue">clinical trials</font></font> take longer to complete than we project, our ability to     execute our current business <font color="blue">strategy will</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Whether or not and how quickly we complete <font color="blue">clinical trials</font> is <font color="blue">dependent</font> in     part upon the rate at which we are able to engage clinical trial sites and,     thereafter, the rate of <font color="blue">enrollment</font> of patients</td>
    </tr>
    <tr>
      <td>Patient <font color="blue">enrollment</font> is a     function of many factors, including the size of the <font color="blue">patient population</font>, the     proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the     study, the existence of <font color="blue">competitive <font color="blue">clinical trials</font></font>, and <font color="blue">whether existing</font> or     new drugs are approved for the <font color="blue">indication</font> we are studying</td>
    </tr>
    <tr>
      <td>We are aware that     other  companies are planning <font color="blue">clinical trials</font> that will seek to enroll     <font color="blue">patients with</font> the <font color="blue">same diseases as</font> we are studying</td>
    </tr>
    <tr>
      <td>In addition, one of our     <font color="blue">current trials</font> for Sulonex is designed to <font color="blue">continue until</font> a pre-determined     number of events have occurred to the <font color="blue">patients enrolled</font></td>
    </tr>
    <tr>
      <td>Trials such as this     are subject to <font color="blue">delays stemming from patient withdrawal</font> and <font color="blue">from lower than</font>     expected <font color="blue">event rates</font> and <font color="blue">may also incur increased costs</font> if <font color="blue">enrollment</font> is     increased in order to achieve the desired number of events</td>
    </tr>
    <tr>
      <td>If we experience     delays  in  identifying  and  contracting with sites and/or in patient     <font color="blue">enrollment</font> in our <font color="blue">clinical trial programs</font>, we may incur <font color="blue">additional</font> costs and     delays in our <font color="blue"><font color="blue">development</font> programs</font>, and may not be able to complete our     <font color="blue">clinical trials</font> on a cost-<font color="blue">effective</font> or <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Additionally, we have finalized an SPA <font color="blue"><font color="blue">agreement</font> with</font> the FDA for the Phase     III and <font color="blue">Phase IV </font><font color="blue">clinical trials</font> of Sulonex</td>
    </tr>
    <tr>
      <td>The clinical plan to support an     NDA approval for Sulonex under subpart H, as agreed upon with the FDA under     an  SPA,  consists  of:  (i) a single <font color="blue">Phase III </font>trial in <font color="blue">patients with</font>     <font color="blue">microalbuminuria</font>  based  on  the  surrogate  marker  of  <font color="blue">regression</font> of     <font color="blue">microalbuminuria</font>  as  the  primary endpoint; (ii) supportive data from     <font color="blue"><font color="blue">previously</font> conducted <font color="blue">clinical studies</font></font>; and (iii) substantial <font color="blue">recruitment</font>     into our <font color="blue">Phase IV </font><font color="blue">confirmatory study</font> that will measure <font color="blue">clinical outcomes</font> in     <font color="blue">patients with</font> overt nephropathy, or <font color="blue">macroalbuminuria</font></td>
    </tr>
    <tr>
      <td>The subpart H process     is complex and requires <font color="blue">careful execution</font></td>
    </tr>
    <tr>
      <td>No assurance can be given that we     will be able to meet the <font color="blue">requirements</font> set forth in the SPA Even if we meet     those <font color="blue">requirements</font>, the FDA is not obligated to <font color="blue">grant approval</font> of our NDA     for Sulonex</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>approves Sulonex for marketing on the basis of our     <font color="blue">Phase III </font>trial, our <font color="blue">Phase IV </font><font color="blue">clinical trial may yield</font> insufficient efficacy     data or give rise to safety concerns, which could result in withdrawal of     <font color="blue">such approval</font> or could cause us to withdraw the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Many companies who have <font color="blue">been granted</font> the right to utilize an <font color="blue">accelerated</font>     approval approach have failed to obtain approval</td>
    </tr>
    <tr>
      <td>Moreover, negative or     <font color="blue">inconclusive</font> results from the <font color="blue">clinical trials</font> we hope to conduct or adverse     <font color="blue">medical events could</font> cause us to have to repeat or terminate the clinical     trials</td>
    </tr>
    <tr>
      <td>Accordingly, we may not be able to complete the <font color="blue">clinical trials</font>     within an acceptable time frame, if at all</td>
    </tr>
    <tr>
      <td>If our <font color="blue">drug <font color="blue">candidates</font></font> do not receive the necessary <font color="blue"><font color="blue">regulatory</font> approval</font>s, we     will be unable to <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have not received, and may never receive, <font color="blue"><font color="blue">regulatory</font> approval</font> for the     <font color="blue">commercial sale</font> of any of our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We will need to conduct     <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font> research</font> and <font color="blue">human testing</font> before we can apply for     product  <font color="blue">approval with</font> the FDA or with <font color="blue">regulatory</font> <font color="blue">authorities</font> of other     countries</td>
    </tr>
    <tr>
      <td>Pre-clinical testing and <font color="blue">clinical <font color="blue">development</font></font> are long, expensive     and <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of <font color="blue">regulatory</font> <font color="blue">requirements</font> typically     depends on the nature, <font color="blue">complexity</font> and novelty of the product and requires     the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Data obtained from pre-clinical     and <font color="blue">clinical tests</font> can be interpreted in different ways, which could delay,     limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>It may take us many years to complete     the testing of our <font color="blue">drug <font color="blue">candidates</font></font> and failure can occur at any stage of     this process</td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font> results or medical events during a     clinical trial could cause us to delay or terminate our <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       Furthermore, interim results of preclinical or <font color="blue">clinical studies</font> do not     <font color="blue">necessarily predict</font> their final results, and acceptable results in early     <font color="blue">studies might</font> not be obtained in <font color="blue">later studies</font></td>
    </tr>
    <tr>
      <td>Drug <font color="blue">candidates</font> in the later     stages of <font color="blue">clinical <font color="blue">development</font></font> may fail to show the desired safety and     <font color="blue">efficacy traits despite</font> positive results in <font color="blue">initial clinical testing</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be no assurance that the results from the <font color="blue">Phase III </font>study will track the     data from the <font color="blue">Phase II </font>study, or that the results from the <font color="blue">Phase IV </font>study     will  yield  sufficient  efficacy  data</td>
    </tr>
    <tr>
      <td>With respect to Sulonex, the     <font color="blue">recommendation</font> to move into our <font color="blue">pivotal program</font>, as well as the announced     <font color="blue">Phase II </font>data, may not be <font color="blue">indicative</font> of results from future <font color="blue">clinical trials</font>     and the <font color="blue">risk remains</font> that the <font color="blue">pivotal program</font> for Sulonex may generate     <font color="blue">efficacy data</font> that will be insufficient for the approval of the drug, or may     <font color="blue">raise safety concerns</font> that <font color="blue">may prevent approval</font> of the drug</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials also</font> have a high risk of failure</td>
    </tr>
    <tr>
      <td>A number of companies in     the  <font color="blue">pharmaceutical</font>  industry, including <font color="blue"><font color="blue">biotechnology</font> companies</font>, have     suffered  <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue">clinical trials</font>, even after     achieving promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>If we experience delays in     the testing or <font color="blue">approval process</font> or if we need to perform more or larger     <font color="blue">clinical trials</font> than originally planned, our financial results and the     <font color="blue">commercial prospects</font> for our <font color="blue">drug <font color="blue">candidates</font></font> may be <font color="blue">materially impaired</font></td>
    </tr>
    <tr>
      <td>In     addition, we have limited experience in conducting and managing the clinical     <font color="blue">trials necessary</font> to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> in the <font color="blue">United States </font>and     abroad and, <font color="blue">accordingly</font>, may encounter unforeseen problems and delays in the     <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>Because all of our <font color="blue">proprietary</font> <font color="blue">technologies</font> are licensed to us by third     parties, <font color="blue">termination</font> of these <font color="blue"><font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> would prevent us from</font>     developing our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not own any of our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have licensed the <font color="blue">patent rights</font>     to these drugs <font color="blue">candidates</font> from others</td>
    </tr>
    <tr>
      <td>These <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> require us     to meet <font color="blue">development</font> or <font color="blue">financing <font color="blue">milestones</font></font> and impose <font color="blue">development</font> and     <font color="blue">commercialization</font> due diligence <font color="blue">requirements</font> on us</td>
    </tr>
    <tr>
      <td>In addition, under these     <font color="blue"><font color="blue">agreement</font>s</font>,  we <font color="blue">must pay royalties on sales</font> of products resulting from     licensed <font color="blue">technologies</font> and pay the patent filing, prosecution and maintenance     costs related to the licenses</td>
    </tr>
    <tr>
      <td>If we do not meet our <font color="blue">obligations</font> in a timely     manner or if we <font color="blue">otherwise breach</font> the terms of our <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font>, our     <font color="blue"><font color="blue">licensors</font> could terminate</font> the <font color="blue"><font color="blue">agreement</font>s</font>, and we would lose the rights to     our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font>     do not <font color="blue">successfully</font> <font color="blue">manufacture</font> our products, our business will be harmed</td>
    </tr>
    <tr>
      <td>We have no experience in <font color="blue"><font color="blue">manufacturing</font> products</font> for clinical or commercial     purposes  and  do  not have any <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>We intend to     continue, in whole or in part, to use <font color="blue">third parties</font> to <font color="blue">manufacture</font> our     products for use in <font color="blue">clinical trials</font> and for <font color="blue">future sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contract  </font><font color="blue">manufacture</font>rs  often  encounter  <font color="blue"><font color="blue">difficult</font>ies</font>  in <font color="blue">scaling up</font>     production, including problems involving production yields, quality control     and assurance, shortage of qualified personnel, <font color="blue">compliance with</font> FDA and     foreign  <font color="blue">regulations</font>,  production  costs  and  <font color="blue">development</font> of advanced     <font color="blue">manufacturing</font> <font color="blue">techniques</font> and process controls</td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">manufacture</font>rs     may not perform as agreed or may not remain in the contract <font color="blue">manufacturing</font>     business for the time required by us to <font color="blue">successfully</font> produce and market our     <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, our contract <font color="blue">manufacture</font>rs will be subject to     ongoing periodic, unannounced <font color="blue">inspections</font> by the FDA and <font color="blue">corresponding</font>     foreign <font color="blue"><font color="blue">government</font>al</font> agencies to ensure strict <font color="blue">compliance with</font>, among other     things,  current  good  <font color="blue">manufacturing</font>  practices, in addition to other     <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font> and <font color="blue">corresponding</font> foreign standards</td>
    </tr>
    <tr>
      <td>We will not     have  <font color="blue">control over</font>, other than by contract, third-party <font color="blue">manufacture</font>rs &amp;apos      <font color="blue">compliance with</font> these <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>Switching or engaging     multiple <font color="blue">manufacture</font>rs may be <font color="blue">difficult</font> because the number of potential     <font color="blue">manufacture</font>rs is limited and, <font color="blue">particularly</font> in the case of Sulonex, the     process by which multiple <font color="blue">manufacture</font>rs make the drug substance must be     identical at each <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>It may be <font color="blue">difficult</font> for us to find     and  engage <font color="blue">replacement</font> or multiple <font color="blue">manufacture</font>rs quickly and on terms     acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>Moreover, if we need to change <font color="blue">manufacture</font>rs,     the FDA and <font color="blue">corresponding</font> foreign <font color="blue">regulatory</font> agencies must approve these     <font color="blue">manufacture</font>rs  in  advance,  which will involve testing and <font color="blue">additional</font>     <font color="blue">inspections</font>  to ensure <font color="blue">compliance with</font> FDA and foreign <font color="blue">regulations</font> and     standards</td>
    </tr>
    <tr>
      <td>If third-party <font color="blue">manufacture</font>rs fail to deliver the required quantities of our     <font color="blue">drug <font color="blue">candidates</font></font> on a <font color="blue">timely basis</font> and <font color="blue">at <font color="blue">commercially</font> reasonable prices</font>, we     will not be able to <font color="blue">commercialize</font> our <font color="blue">products as</font> planned</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________       We have <font color="blue">entered into</font> a <font color="blue">relationship with</font> a US-based contract <font color="blue">manufacture</font>r     for  Sulonex  which we believe will be adequate to satisfy our current     <font color="blue">clinical supply</font> needs; however, as we scale-up for commercial <font color="blue">manufacturing</font>,     we will need to ensure that we <font color="blue"><font color="blue">accurately</font> reproduce</font> the <font color="blue">established process</font>     on a <font color="blue">larger scale</font></td>
    </tr>
    <tr>
      <td>As with all heparin-like compounds, the end product is     <font color="blue">highly sensitive</font> to the <font color="blue">manufacturing</font> process utilized</td>
    </tr>
    <tr>
      <td>Accordingly, as we     scale-up,   <font color="blue">reproducibility</font>   will  be  required  for  the  successful     <font color="blue">commercialization</font> of Sulonex</td>
    </tr>
    <tr>
      <td>Additionally, as we scale-up, we will incur     capital <font color="blue">expenditure</font>s to enable <font color="blue">larger scale</font> production</td>
    </tr>
    <tr>
      <td>If we are not able to obtain the <font color="blue">raw materials</font> required for the <font color="blue">manufacture</font>     of our <font color="blue">lead <font color="blue">product candidate</font></font>, Sulonex, our ability to develop and market     this <font color="blue"><font color="blue">product candidate</font> will</font> be <font color="blue"><font color="blue">substantially</font> harmed</font></td>
    </tr>
    <tr>
      <td>Source materials for Sulonex, our <font color="blue">lead <font color="blue">product candidate</font></font>, are <font color="blue">derived from</font>     porcine  mucosa</td>
    </tr>
    <tr>
      <td>Long-term  supplies for Sulonex could be <font color="blue">affected by</font>     <font color="blue">limitations</font> in the supply of <font color="blue">porcine mucosa</font> and the demand for other heparin     products,  over  which we will have no control</td>
    </tr>
    <tr>
      <td>Additionally, diseases     <font color="blue">affecting</font>  the  <font color="blue">world supply</font> of pigs could have an actual or perceived     negative  impact  on  our  ability,  or  the  ability  of our contract     <font color="blue">manufacture</font>rs, to source, make and/or sell Sulonex</td>
    </tr>
    <tr>
      <td>Such <font color="blue">negative impact</font>     <font color="blue">could materially affect</font> the <font color="blue">commercial success</font> of Sulonex</td>
    </tr>
    <tr>
      <td>If we do not establish or maintain <font color="blue">manufacturing</font>, drug <font color="blue">development</font> and     marketing <font color="blue">arrangements</font> with <font color="blue">third parties</font>, we may be unable to <font color="blue">commercialize</font>     our products</td>
    </tr>
    <tr>
      <td>We are an <font color="blue">emerging company</font> and do not possess all of the <font color="blue">capabilities</font> to     fully <font color="blue">commercialize</font> our <font color="blue">products on</font> our own</td>
    </tr>
    <tr>
      <td>From time to time, we may need     to contract with <font color="blue">third parties</font> to:                                           ●       <font color="blue">manufacture</font> our product <font color="blue">candidates</font>;                                           ●       <font color="blue">assist us</font> in developing, testing and obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> for and     <font color="blue">commercializing</font> some of our compounds and <font color="blue">technologies</font>; and                                           ●       market and distribute our <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>We can <font color="blue">provide no assurance</font> that we will be able to <font color="blue">successfully</font> enter into     <font color="blue"><font color="blue">agreement</font>s</font> with such <font color="blue">third parties</font> on terms that are acceptable to us, if at     all</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> contract with <font color="blue">third parties</font> for these     services when needed, or if <font color="blue">existing <font color="blue">arrangements</font></font> for these services are     terminated, whether or not through our actions, or if such <font color="blue">third parties</font> do     not fully perform under these <font color="blue">arrangements</font>, we may have to delay, scale back     or end one or more of our drug <font color="blue"><font color="blue">development</font> programs</font> or seek to develop or     <font color="blue">commercialize</font> our products in<font color="blue">dependent</font>ly, which could result in delays</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">such failure could</font> result in the <font color="blue">termination</font> of <font color="blue">license rights</font>     to one or more of our products</td>
    </tr>
    <tr>
      <td>If these <font color="blue">manufacturing</font>, <font color="blue">development</font> or     marketing <font color="blue"><font color="blue">agreement</font>s</font> take the form of a <font color="blue">partnership</font> or <font color="blue">strategic alliance</font>,     such <font color="blue">arrangements</font> may provide our <font color="blue"><font color="blue">collaborators</font> with <font color="blue">significant</font> discretion</font>     in  determining  the efforts and resources that they will apply to the     <font color="blue">development</font> and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Accordingly, to the     extent that we <font color="blue">rely on <font color="blue">third parties</font></font> to research, develop or <font color="blue">commercialize</font>     our  products,  we are unable to <font color="blue">control whether such <font color="blue">products will</font></font> be     <font color="blue">scientifically</font> or <font color="blue"><font color="blue">commercially</font> successful</font></td>
    </tr>
    <tr>
      <td>Our reliance on <font color="blue">third parties</font>, such as clinical research <font color="blue">organization</font>s, or     CROs, may result in delays in completing, or a failure to complete, clinical     trials if they fail to perform under our <font color="blue"><font color="blue">agreement</font>s</font> with them</td>
    </tr>
    <tr>
      <td>In the course of product <font color="blue">development</font>, we engage CROs to conduct and manage     <font color="blue">clinical studies</font> and to <font color="blue">assist us</font> in guiding our <font color="blue">products through</font> the FDA     review and <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>Because we have engaged and intend to continue     to engage CROs to help us obtain <font color="blue">market approval</font> for our <font color="blue">drug <font color="blue">candidates</font></font>,     many important aspects of this process have been and will be out of our     direct control</td>
    </tr>
    <tr>
      <td><font color="blue">If the CROs </font>fail to perform their <font color="blue">obligations</font> under our     <font color="blue"><font color="blue">agreement</font>s</font> with them or fail to perform <font color="blue">clinical trials</font> in a satisfactory     manner, we <font color="blue">may face delays</font> in completing our <font color="blue">clinical trials</font>, as well as     <font color="blue">commercialization</font> of one or more <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Furthermore, any loss or     delay  in  obtaining  contracts  with such entities may also delay the     <font color="blue">completion</font>  of  our  clinical  trials  and the <font color="blue">market approval</font> of drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Other Risks Related to Our Business       If  we are unable to develop adequate sales, marketing or <font color="blue">distribution</font>     <font color="blue">capabilities</font> or enter into <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">third parties</font> to perform some of     these  functions,  we  will  not be able to <font color="blue">commercialize</font> our products     <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>In the event Sulonex is <font color="blue">approved by</font> the FDA, we currently plan to conduct     our own sales and <font color="blue">marketing effort</font> to support the drug, and we may adopt     this <font color="blue">strategy with respect</font> to future <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>We currently have no     experience in sales, marketing or <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">directly market</font> and     distribute any products, we must build a sales and <font color="blue">marketing <font color="blue">organization</font></font>     <font color="blue">with <font color="blue">appropriate</font> technical expertise</font> and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We may     attempt to <font color="blue">build such</font> a sales and <font color="blue">marketing <font color="blue">organization</font></font> on our own or with     the  assistance  of  a  contract  sales  <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>For some market     <font color="blue">opportunities</font>, we may need to enter into co-promotion or other licensing     <font color="blue">arrangements</font> with larger <font color="blue">pharmaceutical</font> or <font color="blue"><font color="blue">biotechnology</font> firms</font> in order to     increase the <font color="blue">commercial success</font> of our products</td>
    </tr>
    <tr>
      <td>We may not be able to     establish sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font> of our own or enter     into  such  <font color="blue">arrangements</font>  with  <font color="blue">third parties</font> in a <font color="blue">timely manner</font> or on     acceptable terms</td>
    </tr>
    <tr>
      <td>To the extent that we enter into co-promotion or other     licensing <font color="blue">arrangements</font>, our <font color="blue">product revenues</font> are likely to be lower than if     we <font color="blue">directly market</font>ed and sold our products, and some or all of the revenues     we receive <font color="blue">will depend upon</font> the efforts of <font color="blue">third parties</font>, and these efforts     may not be successful</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">building marketing</font> and <font color="blue">distribution</font>     <font color="blue">capabilities</font> may be more <font color="blue">expensive than</font> we anticipate, requiring us to     <font color="blue">divert capital from</font> other <font color="blue">intended purposes</font> or <font color="blue">preventing us from building</font>     our marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font> to the desired levels</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       Even if we obtain FDA approval to market our <font color="blue">drug products</font>, if they fail to     achieve <font color="blue">market <font color="blue">acceptance</font></font>, we <font color="blue">will never record meaningful revenues</font></td>
    </tr>
    <tr>
      <td>Even if our products are approved for sale, they may not be <font color="blue">commercially</font>     successful in the marketplace</td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our <font color="blue">drug products</font> will     <font color="blue">depend on</font> a number of factors, including:                                         ●       <font color="blue">perceptions by members</font> of the <font color="blue"><font color="blue">health care</font> community</font>, including physicians,     of the safety and efficacy of our product <font color="blue">candidates</font>;                                         ●       the rates of adoption of our <font color="blue">products by medical practitioners</font> and the     <font color="blue">target populations</font> for our products;                                         ●       the <font color="blue">potential advantages</font> that our <font color="blue">products offer over existing treatment</font>     methods;                                         ●       the cost-<font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">products relative</font> to <font color="blue">competing products</font>;                                         ●       the <font color="blue">availability</font> of <font color="blue">government</font> or third-party payor <font color="blue">reimbursement</font> for our     products;                                         ●       the side effects or <font color="blue">unfavorable publicity concerning</font> our products or similar     products; and                                         ●       the <font color="blue"><font color="blue">effective</font>ness</font> of our sales, marketing and <font color="blue">distribution</font> efforts</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  expect  sales  of  our products, if approved, to generate     <font color="blue">substantially</font> all of our revenues in the long-term, the failure of our drugs     to find <font color="blue">market <font color="blue">acceptance</font></font> would harm our business and could require us to     seek <font color="blue">additional</font> financing or other sources of revenue</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop and <font color="blue">market products</font> that are <font color="blue">less expensive</font>, more     <font color="blue">effective</font> or <font color="blue">safer than</font> our <font color="blue">drug products</font>, our commercial <font color="blue">opportunities</font> may     be reduced or eliminated</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> industry is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include     <font color="blue">pharmaceutical</font>  companies  and  <font color="blue">biotechnology</font>  companies,  as  well as     <font color="blue">universities</font> and public and <font color="blue">private research institutions</font></td>
    </tr>
    <tr>
      <td>In addition,     companies  that  are  active in <font color="blue">different but</font> related <font color="blue">fields represent</font>     substantial <font color="blue">competition</font> for us</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue"><font color="blue">significant</font>ly</font>     greater  capital resources, larger research and <font color="blue">development</font> staffs and     <font color="blue">facilities</font>  and  greater  experience  in drug <font color="blue">development</font>, regulation,     <font color="blue">manufacturing</font> and marketing than we do</td>
    </tr>
    <tr>
      <td>These <font color="blue">organization</font>s also compete     with us to recruit qualified personnel, attract partners for <font color="blue">joint ventures</font>     or other <font color="blue">collaborations</font>, and license <font color="blue">technologies</font> that are <font color="blue">competitive with</font>     ours</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">competitors</font> may be able to more easily develop     <font color="blue">technologies</font> and products that could render our <font color="blue">drug products</font> obsolete or     <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>To compete <font color="blue">successfully</font> in this industry we must identify     novel  and  <font color="blue">unique drugs</font> or methods of treatment and then complete the     <font color="blue">development</font> of those <font color="blue">drugs as treatments</font> in advance of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The  drugs that we are attempting to develop will have to <font color="blue">compete with</font>     <font color="blue">existing therapies</font></td>
    </tr>
    <tr>
      <td>In addition, our commercial <font color="blue">opportunities</font> may be reduced     or eliminated if our <font color="blue">competitors</font> develop and <font color="blue">market products</font> that are less     expensive, more <font color="blue">effective</font> or <font color="blue">safer than</font> our <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>Other companies     have  drug  <font color="blue">candidates</font>  in  <font color="blue">various stages</font> of pre-clinical or clinical     <font color="blue">development</font> to <font color="blue">treat diseases</font> for which we are <font color="blue">also seeking</font> to discover and     develop <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>Some of these potential competing drugs are further     advanced in <font color="blue">development</font> than our <font color="blue">drug <font color="blue">candidates</font></font> and may be <font color="blue">commercialize</font>d     earlier</td>
    </tr>
    <tr>
      <td>Even if we are successful in developing <font color="blue">effective</font> drugs, our     products  may  not  compete <font color="blue">successfully</font> with products produced by our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       If we lose our <font color="blue">key personnel</font> or are unable to attract and retain <font color="blue">additional</font>     personnel, our <font color="blue"><font color="blue">operations</font> could</font> be disrupted and our business could be     harmed</td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">February  </font>28, 2006, we had 29 full and part-time employees</td>
    </tr>
    <tr>
      <td>To     <font color="blue">successfully</font> develop our <font color="blue">drug <font color="blue">candidates</font></font>, we must be able to attract and     retain <font color="blue">highly skilled personnel</font></td>
    </tr>
    <tr>
      <td>In addition, if we lose the services of our     <font color="blue">current personnel</font>, in particular, Michael S Weiss, our Chairman and Chief     Executive Officer, our ability to continue to execute on our business plan     could be <font color="blue">materially impaired</font></td>
    </tr>
    <tr>
      <td>In addition, although we have an <font color="blue">employment</font>     <font color="blue">agreement</font>  with  Mr</td>
    </tr>
    <tr>
      <td>Weiss,  this <font color="blue">agreement</font> does not <font color="blue">prevent him from</font>     <font color="blue">terminating</font> his <font color="blue">employment</font> with us</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">acquisition</font>s</font> we make may require a <font color="blue"><font color="blue">significant</font> amount</font> of our available     cash and may not be <font color="blue">scientifically</font> or <font color="blue"><font color="blue">commercially</font> successful</font></td>
    </tr>
    <tr>
      <td>As part of our business strategy, we may effect <font color="blue"><font color="blue">acquisition</font>s</font> to obtain     <font color="blue">additional</font> businesses, products, <font color="blue">technologies</font>, <font color="blue">capabilities</font> and personnel</td>
    </tr>
    <tr>
      <td>If we make one or more <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font> in which the <font color="blue">consideration</font>     includes  cash, we may be required to use a substantial portion of our     <font color="blue">available cash</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>involve a number of <font color="blue">operational risks</font>, including:                                         ●       <font color="blue">difficult</font>y and expense of <font color="blue">assimilating</font> the <font color="blue">operations</font>, technology and     personnel of the acquired business;                                         ●       our <font color="blue">inability</font> to retain the <font color="blue">management</font>, <font color="blue">key personnel</font> and other employees of     the acquired business;                                         ●       our <font color="blue">inability</font> to maintain the acquired companyapstas <font color="blue">relationship with</font> key third     parties, such as alliance partners;                                         ●       exposure to legal claims for <font color="blue">activities</font> of the acquired business prior to     the <font color="blue">acquisition</font>;                                         ●       the diversion of our <font color="blue">management</font>apstas attention from our core business; and                                         ●       the <font color="blue">potential impairment</font> of goodwill and write-off of in-process research     and <font color="blue">development</font> costs, <font color="blue">adversely</font> <font color="blue">affecting</font> our reported results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The status of <font color="blue">reimbursement</font> from third-party payors for <font color="blue">newly approved</font>     <font color="blue"><font color="blue">health care</font> drugs</font> is uncertain and failure to obtain <font color="blue">adequate <font color="blue">reimbursement</font></font>     <font color="blue">could limit</font> our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> <font color="blue">pharmaceutical</font> products may depend, in part, on     the extent to <font color="blue">which <font color="blue">reimbursement</font></font> for the <font color="blue">products will</font> be <font color="blue">available from</font>:                                         ●       <font color="blue">government</font> and health administration <font color="blue">authorities</font>;                                         ●       <font color="blue">private health insurers</font>;                                         ●       <font color="blue">managed care programs</font>; and                                         ●       other third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue"><font color="blue">reimbursement</font> status</font> of newly     <font color="blue">approved <font color="blue">health care</font> products</font></td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare, are     <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government     </font>and other third-party payors increasingly are attempting to <font color="blue">contain health</font>     <font color="blue">care costs by limiting both coverage</font> and the level of <font color="blue">reimbursement</font> for new     drugs  and by refusing, in some cases, to <font color="blue">provide coverage</font> for uses of     <font color="blue">approved products</font> for disease <font color="blue">indication</font>s for which the FDA has not granted     <font color="blue">labeling approval</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue"><font color="blue">insurance coverage</font> may</font> not be available to     patients for our products</td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and other third-party payors do not     <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels for our products, their     <font color="blue">market <font color="blue">acceptance</font></font> may be reduced</td>
    </tr>
    <tr>
      <td>Health <font color="blue">care reform measures could <font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>The business and <font color="blue">financial condition</font> of <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font>     companies are <font color="blue">affected by</font> the efforts of <font color="blue"><font color="blue">government</font>al</font> and third-party payors     to contain or reduce the costs of <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States </font>and in     foreign  <font color="blue">jurisdictions</font>  there have been, and we expect that <font color="blue">there will</font>     continue to be, a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font> proposals aimed at     changing the <font color="blue">health care</font> system, such as those relating to <font color="blue">reimportation</font> of     <font color="blue">drugs into</font> the US from other countries where they are sold at a lower     price and <font color="blue">government</font> control of <font color="blue">prescription drug pricing</font></td>
    </tr>
    <tr>
      <td>The pendency or     approval of <font color="blue">such proposals could</font> result in a decrease in our stock price or     limit our ability to <font color="blue">raise capital</font> or to obtain strategic <font color="blue">partnership</font>s or     licenses</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________       We <font color="blue">face product <font color="blue">liability</font> risks</font> and may not be able to obtain adequate     insurance</td>
    </tr>
    <tr>
      <td>The use of our <font color="blue">drug <font color="blue">candidates</font></font> in <font color="blue">clinical trials</font>, and the future sale of     any <font color="blue">approved products</font>, exposes us to <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Although we are not     aware of any historical or anticipated product <font color="blue">liability</font> claims <font color="blue">against us</font>,     if we cannot <font color="blue">successfully</font> defend ourselves against product <font color="blue">liability</font> claims,     we may incur substantial <font color="blue">liabilities</font> or be required to cease <font color="blue">clinical trials</font>     of our <font color="blue">drug <font color="blue">candidates</font></font> or limit <font color="blue">commercialization</font> of any <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>We believe that we have obtained sufficient product <font color="blue">liability</font> insurance     coverage for our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We intend to expand our <font color="blue">insurance coverage</font>     to  include  the <font color="blue">commercial sale</font> of any <font color="blue">approved products</font> if marketing     approval is obtained; however, <font color="blue">insurance coverage</font> is <font color="blue">becoming increasingly</font>     expensive</td>
    </tr>
    <tr>
      <td>We may not be able to maintain <font color="blue">insurance coverage</font> at a reasonable     cost</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font> <font color="blue">insurance coverage</font> that will     be adequate to cover product <font color="blue">liability</font> risks that may arise</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of     merit or eventual outcome, product <font color="blue">liability</font> claims may result in:                                         ●       decreased demand for a product;                                         ●       injury to our reputation;                                         ●       our <font color="blue">inability</font> to continue to develop a <font color="blue">drug candidate</font>;                                         ●       withdrawal of <font color="blue">clinical trial volunteers</font>; and                                         ●       loss of revenues</td>
    </tr>
    <tr>
      <td>Consequently, a product <font color="blue">liability</font> claim or product recall may result in     losses that could be material</td>
    </tr>
    <tr>
      <td>In  <font color="blue">connection</font>  with  providing our <font color="blue">clinical trial <font color="blue">management</font></font> and site     <font color="blue">recruitment</font> services, we may be exposed to <font color="blue">liability</font> that could have a     material  adverse  effect  on  our  <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Online Collaborative Oncology Group, Inc, or OCOG, a subsidiary we     acquired through our <font color="blue">acquisition</font> of ACCESS Oncology, <font color="blue">provides clinical trial</font>     <font color="blue">management</font>  and  site  <font color="blue">recruitment</font>  services  to  us  as well as other     <font color="blue">biotechnology</font> and <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>In conducting the <font color="blue">activities</font> of     OCOG,  any  failure on our part to <font color="blue">comply with</font> applicable <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">regulations</font> or <font color="blue">contractual</font> <font color="blue">obligations</font> could expose us to <font color="blue">liability</font> to our     clients and could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We also could be     held liable for errors or omissions in <font color="blue">connection</font> with the services we     perform</td>
    </tr>
    <tr>
      <td>In addition, the wrongful or erroneous delivery of <font color="blue">health care</font>     information or <font color="blue">services may expose us</font> to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If we were required to     pay damages or bear the costs of defending any such claims, the <font color="blue">losses could</font>     be material</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate compliance efforts cannot guarantee</font> that we are in compliance     with all potentially applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacturing</font>, pricing, sales, and <font color="blue">reimbursement</font> of our     products, together with our general <font color="blue">operations</font>, are subject to extensive     <font color="blue">regulation by federal</font>, state and other <font color="blue">authorities</font> within the <font color="blue">United States </font>    and numerous entities outside <font color="blue">of the United States</font></td>
    </tr>
    <tr>
      <td>We are a <font color="blue">relatively</font>     small company with 29 employees</td>
    </tr>
    <tr>
      <td>We also have <font color="blue"><font color="blue">significant</font>ly</font> fewer employees     than  many other companies that have a <font color="blue">product candidate</font> in late-stage     <font color="blue">clinical <font color="blue">development</font></font>, and we rely heavily on <font color="blue">third parties</font> to conduct many     <font color="blue">important functions</font></td>
    </tr>
    <tr>
      <td>While we have developed and instituted a corporate     <font color="blue">compliance program <font color="blue">based on</font></font> what we believe are the <font color="blue">current best practices</font>,     we  cannot  assure  you  that we are or will be in <font color="blue">compliance with</font> all     potentially applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> any of these     <font color="blue">regulations</font> we could be subject to a range of <font color="blue">regulatory</font> actions, including     suspension or <font color="blue">termination</font> of <font color="blue">clinical trials</font>, the failure to approve a     <font color="blue">product candidate</font>, restrictions on our products or <font color="blue">manufacturing</font> processes,     withdrawal  of  products  from the market, <font color="blue">significant</font> fines, or other     sanctions or <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Financial Condition       Our current cash, cash equivalents and <font color="blue">investment</font> securities may not be     adequate  to  support our <font color="blue">operations</font> for the next 24 months as we have     estimated</td>
    </tr>
    <tr>
      <td>We believe that our dlra100dtta7 million in cash, cash equivalents, interest     receivable  and  <font color="blue">investment</font> securities as of <font color="blue">December </font>31, 2005 will be     sufficient to <font color="blue">enable us</font> to meet our planned operating needs and capital     <font color="blue">expenditure</font>s for at least the next 24 months</td>
    </tr>
    <tr>
      <td>Our forecast of the period of     time <font color="blue">through which</font> our cash, cash equivalents, interest receivable and     <font color="blue">investment</font>  <font color="blue">securities will</font> be adequate to support our <font color="blue">operations</font> is a     forward-looking statement that <font color="blue">involves risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These factors include the following:       23       _________________________________________________________________                                         ●       the timing of expenses associated with <font color="blue">manufacturing</font> and product <font color="blue">development</font>     of the <font color="blue">proprietary</font> <font color="blue">drug <font color="blue">candidates</font></font> within our portfolio and those that may     be in-licensed, partnered or acquired;                                         ●       the timing of the in-licensing, partnering and <font color="blue">acquisition</font> of new product     <font color="blue">opportunities</font>;                                         ●       the progress of the <font color="blue"><font color="blue">development</font> efforts</font> of <font color="blue">parties with whom</font> we have     entered, or may enter, into research and <font color="blue">development</font> <font color="blue"><font color="blue">agreement</font>s</font>;                                         ●       our ability to achieve our <font color="blue"><font color="blue">milestones</font> under</font> our licensing <font color="blue">arrangements</font>; and                                         ●       the <font color="blue">costs involved</font> in prosecuting and <font color="blue">enforcing patent</font> claims and other     <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">additional</font> funds on terms favorable to us, or at     all, our business would be harmed</td>
    </tr>
    <tr>
      <td>We  expect to use, rather than generate, funds from <font color="blue">operations</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Based on our current plans, we believe our <font color="blue">existing cash</font>     and cash equivalents, interest receivable and <font color="blue">investment</font> <font color="blue">securities will</font> be     sufficient to fund our operating expenses and capital <font color="blue">requirements</font> for at     least the next 24 months; however, the <font color="blue">actual amount</font> of funds that we will     need prior to or after that date will be determined by many factors, some of     which are beyond our control</td>
    </tr>
    <tr>
      <td>As a result, we may need funds sooner or in     <font color="blue">different amounts than</font> we currently anticipate, <font color="blue">depending upon</font>:                                         ●       the progress of our <font color="blue">development</font> <font color="blue">activities</font>;                                         ●       the progress of our research <font color="blue">activities</font>;                                         ●       the number and scope of our <font color="blue"><font color="blue">development</font> programs</font>;                                         ●       the costs associated with <font color="blue">commercialization</font> <font color="blue">activities</font>, including     <font color="blue">manufacturing</font>, marketing and sales;                                         ●       our ability to establish and maintain current and <font color="blue">new licensing</font> or     <font color="blue">acquisition</font> <font color="blue">arrangements</font>;                                         ●       our ability to achieve our <font color="blue"><font color="blue">milestones</font> under</font> our licensing <font color="blue">arrangements</font>;                                         ●       the <font color="blue">costs involved</font> in <font color="blue">enforcing patent</font> claims and other <font color="blue">intellectual</font>     <font color="blue">property rights</font>; and                                         ●       the costs and timing of <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>If  our  capital  resources  are  insufficient  to <font color="blue">meet future capital</font>     <font color="blue">requirements</font>, we will have to raise <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>If we are unable to     obtain  <font color="blue">additional</font> funds on terms favorable to us or at all, we may be     required to cease or reduce our operating <font color="blue">activities</font> or sell or license to     third  parties  some  or all of our <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>If we raise     <font color="blue">additional</font> funds by selling <font color="blue">additional</font> shares of our <font color="blue">capital stock</font>, the     <font color="blue">ownership interests</font> of our <font color="blue"><font color="blue">stockholders</font> will</font> be diluted</td>
    </tr>
    <tr>
      <td>If we need to raise     <font color="blue">additional</font> funds through the sale or license of our <font color="blue">intellectual</font> property,     we may be unable to do so on terms favorable to us</td>
    </tr>
    <tr>
      <td>Our  prior  <font color="blue">restructurings</font>  may  result  in <font color="blue">additional</font> Israeli-related     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>In July 2003, our Israeli <font color="blue">subsidiary vacated</font> its <font color="blue">Jerusalem </font><font color="blue">facility</font>, after     <font color="blue">giving advance</font> notice to the landlord</td>
    </tr>
    <tr>
      <td>On May 1, 2005, the landlord of the     <font color="blue">Jerusalem </font><font color="blue">facility</font> filed suit in Israel claiming that we were <font color="blue">liable as</font> a     result of the alleged breach of the lease <font color="blue">agreement</font> by our subsidiary</td>
    </tr>
    <tr>
      <td>The     amount  <font color="blue">demanded by</font> the landlord totals 4cmam345cmam313 NIS or <font color="blue">approximately</font>     dlra946cmam000 at the <font color="blue">December </font>31, 2005 exchange rate, and includes rent for the     <font color="blue">entire remaining term</font> of the lease, as well as property taxes and other     <font color="blue">costs allegedly incurred by</font> the landlord</td>
    </tr>
    <tr>
      <td>In August 2003, the landlord     claimed a <font color="blue">bank deposit</font>, in the amount of dlra222cmam000, which was <font color="blue">previously</font>     <font color="blue">provided as security</font> in <font color="blue">connection</font> with the lease <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We intend to     <font color="blue">vigorously defend</font> the suit</td>
    </tr>
    <tr>
      <td>filed an answer to the landlord’s complaint</td>
    </tr>
    <tr>
      <td>filed an answer to the     landlord’s complaint</td>
    </tr>
    <tr>
      <td>Generally, each answer <font color="blue">challenges</font> the merits of the     landlord’s cause of <font color="blue">action as</font> to <font color="blue">each defendant</font></td>
    </tr>
    <tr>
      <td>All defendants, except     Keryx (Israel) Ltd, have also filed a motion to dismiss the complaint</td>
    </tr>
    <tr>
      <td>The     plaintiff has filed a response to each answer and a hearing date has been     set by the <font color="blue">Circuit Court of Jerusalem</font></td>
    </tr>
    <tr>
      <td>To date, we have not yet recorded a     charge to reflect any potential <font color="blue">liability</font> associated with this <font color="blue">lawsuit as</font> it     is too early to <font color="blue">accurately</font> estimate the amount of the charge, if any</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________       <font color="blue">In September </font>2001, one of our Israeli <font color="blue">subsidiaries</font> received the status of an      &amp;quote Approved Enterprise, &amp;quote  a <font color="blue">status which grants certain <font color="blue">tax benefits</font></font> in <font color="blue">Israel     </font>in <font color="blue">accordance</font> with the  &amp;quote Law for the Encouragement of Capital Investments,     1959 &amp;quote</td>
    </tr>
    <tr>
      <td>Through <font color="blue">December </font>31, 2003, our Israeli subsidiary, which ceased     <font color="blue">operations</font> in 2003, has received <font color="blue">tax benefits</font> in the form of <font color="blue">exemptions</font> of     <font color="blue">approximately</font>  dlra744cmam000  as  a result of our subsidiaryapstas status as an      &amp;quote <font color="blue">Approved Enterprise </font>&amp;quote</td>
    </tr>
    <tr>
      <td>As part of the restructuring implemented during 2003,     we closed down our <font color="blue">Jerusalem </font>laboratory <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In October 2003, the     subsidiary received a <font color="blue">letter from</font> the <font color="blue">Israeli <font color="blue">Ministry of Industry and Trade </font>    </font>that its <font color="blue">Approved Enterprise </font>status was <font color="blue">cancelled as</font> of July 2003 and that     <font color="blue">past benefits would</font> not need to be repaid</td>
    </tr>
    <tr>
      <td><font color="blue">The Israeli </font>tax <font color="blue">authorities</font> have     yet to confirm this position; however, we believe that, <font color="blue">based on</font> the letter     received from the Ministry of Industry and Trade, it is unlikely that past     <font color="blue">benefits will</font> need to be repaid, and therefore, we have not recorded any     <font color="blue">charge with respect</font> to this potential <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font>     that the Israeli tax <font color="blue">authorities</font> will confirm this position</td>
    </tr>
    <tr>
      <td>As a result, we     may be liable to repay some or all of the <font color="blue">tax benefits</font> received to date,     <font color="blue">which could <font color="blue">adversely</font> affect</font> our <font color="blue">cash flow</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Intellectual Property        If we are unable to <font color="blue">adequately protect</font> our <font color="blue">intellectual</font> property, third     <font color="blue">parties may</font> be able to use our <font color="blue">intellectual</font> property, which could <font color="blue">adversely</font>     affect our ability to compete in the market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> will depend in part on our ability and the ability of     our <font color="blue">licensors</font> to obtain and maintain <font color="blue"><font color="blue">patent protection</font> on</font> our <font color="blue">drug products</font>     and <font color="blue">technologies</font> and <font color="blue">successfully</font> defend these patents against third-party     <font color="blue">challenges</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font>     companies can be <font color="blue">highly uncertain</font> and <font color="blue">involve complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> regarding the breadth of claims allowed in     <font color="blue">biotechnology</font> patents has emerged to date</td>
    </tr>
    <tr>
      <td>Accordingly, the patents we use     may  not  be  <font color="blue">sufficiently</font> broad to prevent others from practicing our     <font color="blue">technologies</font> or from developing <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">others may</font>     in<font color="blue">dependent</font>ly develop similar or alternative <font color="blue">drug products</font> or <font color="blue">technologies</font>     or <font color="blue">design around</font> our patented <font color="blue">drug products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The patents we     use may be challenged or invalidated or may fail to <font color="blue">provide us with</font> any     <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> to protect our <font color="blue">intellectual</font> property where we     believe <font color="blue">patent protection</font> is not <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>Trade secrets     are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>While we require our employees, <font color="blue">collaborators</font> and     <font color="blue">consultants</font>  to enter into <font color="blue">confidentiality</font> <font color="blue"><font color="blue">agreement</font>s</font>, this may not be     sufficient to <font color="blue">adequately protect</font> our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>In addition, we share ownership and <font color="blue">publication rights</font> to data     relating to some of our <font color="blue">drug products</font> and <font color="blue">technologies</font> with our research     <font color="blue">collaborators</font>  and  scientific  advisors</td>
    </tr>
    <tr>
      <td>If  we  cannot maintain the     <font color="blue">confidentiality</font>  of  this  information,  our ability to receive patent     protection or protect our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information     will be at risk</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or third-party claims of <font color="blue">intellectual</font> property <font color="blue">infringement</font> could     require us to spend substantial time and money defending such claims and     <font color="blue">adversely</font> affect our ability to develop and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> assert that we are using their <font color="blue">proprietary</font> <font color="blue">intellectual</font>     <font color="blue">property without authorization</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font> may have or     obtain  patents  in  the  future  and  claim that our <font color="blue">drug products</font> or     <font color="blue">technologies</font> infringe their patents</td>
    </tr>
    <tr>
      <td>If we are required to <font color="blue">defend against</font>     patent suits brought by <font color="blue">third parties</font>, or if we sue <font color="blue">third parties</font> to protect     our <font color="blue">patent rights</font>, we may be required to pay substantial <font color="blue">litigation</font> costs,     and our <font color="blue">management</font>apstas attention may be <font color="blue">diverted from</font> operating our business</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">legal action against</font> our <font color="blue">licensors</font> or us that <font color="blue">seeks damages</font>     or an injunction of our commercial <font color="blue">activities</font> relating to the affected our     <font color="blue">drug products</font> or <font color="blue">technologies</font> could subject us to monetary <font color="blue">liability</font> and     require our <font color="blue">licensors</font> or us to obtain a license to continue to use the     affected our <font color="blue">drug products</font> or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict whether</font> our     <font color="blue">licensors</font> or we <font color="blue">would prevail</font> in any of these types of actions or that any     required <font color="blue">license would</font> be made available on <font color="blue">commercially</font> acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       Concentration of ownership of our <font color="blue">common stock</font> among our existing executive     officers, <font color="blue">directors</font> and principal <font color="blue">stockholders</font> may prevent new investors     from <font color="blue">influencing</font> <font color="blue">significant</font> corporate <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, our executive officers, <font color="blue">directors</font> and principal     <font color="blue">stockholders</font>  (including  their affiliates) beneficially owned, in the     aggregate, <font color="blue">approximately</font> 21dtta7prca of our outstanding <font color="blue">common stock</font>, including,     for this purpose, currently exercisable options and warrants held by our     executive officers, <font color="blue">directors</font> and principal <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As a result, these     persons, acting together, may have the ability to <font color="blue"><font color="blue">significant</font>ly</font> influence     the outcome of all matters submitted to our <font color="blue">stockholders</font> for approval,     including  the  election  and  removal  of  <font color="blue">directors</font>  and any merger,     <font color="blue">consolidation</font>  or  sale  of all or <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td>In     addition, such persons, acting together, may have the ability to <font color="blue"><font color="blue">effective</font>ly</font>     control our <font color="blue">management</font> and affairs</td>
    </tr>
    <tr>
      <td>Accordingly, this <font color="blue">concentration</font> of     <font color="blue">ownership may depress</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       Future sales or other issuances of our <font color="blue">common stock</font> could depress the market     for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales  of  a  substantial number of shares of our <font color="blue">common stock</font>, or the     <font color="blue">perception by</font> the market that those sales could occur, could cause the     <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline or could make it more <font color="blue">difficult</font>     for us to <font color="blue">raise funds through</font> the sale of equity in the future</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>    30, 2005, we <font color="blue">filed with</font> the SEC a shelf <font color="blue">registration</font> statement on Form S-3,     that was declared <font color="blue">effective</font> by the SEC on January 13, 2006, providing for     the  offering  of up to dlra150 million of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Future sales     pursuant to this <font color="blue">registration</font> statement could depress the market for our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we make one or more <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font> in which the <font color="blue">consideration</font>     includes stock or other securities, your equity in us may be <font color="blue"><font color="blue">significant</font>ly</font>     diluted</td>
    </tr>
    <tr>
      <td>We may be required to issue up to 3cmam372cmam422 shares of our common     stock to former <font color="blue">stockholders</font> <font color="blue">of <font color="blue">ACCESS Oncology </font></font>upon the <font color="blue">achievement</font> of     <font color="blue">certain <font color="blue">milestones</font></font></td>
    </tr>
    <tr>
      <td>In addition, we may enter into <font color="blue">arrangements</font> with third     <font color="blue">parties permitting us</font> to <font color="blue">issue shares</font> of <font color="blue">common stock</font> in lieu of certain     <font color="blue">cash payments upon</font> the <font color="blue">achievement</font> of <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, our executive officers, <font color="blue">directors</font>, and principal     <font color="blue">stockholders</font> beneficially own, in the aggregate, <font color="blue">approximately</font> 21dtta7prca of our     <font color="blue">common stock</font>, including <font color="blue">currently exercisable warrants</font> and options held by     them</td>
    </tr>
    <tr>
      <td>If some or all of them should decide to sell a substantial number of     their holdings, it could have a material adverse effect on the market for     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our stock price can be volatile, which increases the risk of <font color="blue">litigation</font>, and     may result in a <font color="blue">significant</font> decline in the value of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> is likely to be <font color="blue">highly volatile</font> and     subject to <font color="blue">wide fluctuations</font> in price in response to <font color="blue">various factors</font>, many     of which are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include:                                         ●       <font color="blue">development</font>s concerning our <font color="blue">drug <font color="blue">candidates</font></font>;                                         ●       <font color="blue">announcements</font> of <font color="blue">technological innovations by us</font> or our <font color="blue">competitors</font>;                                         ●       <font color="blue">introductions</font> or <font color="blue">announcements</font> of <font color="blue">new products by us</font> or our <font color="blue">competitors</font>;                                         ●       <font color="blue">announcements</font> by us of <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font>, strategic <font color="blue">partnership</font>s,     <font color="blue">joint ventures</font> or <font color="blue">capital commitments</font>;                                         ●       changes in financial estimates <font color="blue">by securities analysts</font>;                                         ●       actual or anticipated <font color="blue">variations</font> in quarterly operating results;                                         ●       expiration or <font color="blue">termination</font> of licenses, research contracts or other     collaboration <font color="blue"><font color="blue">agreement</font>s</font>;                                         ●       <font color="blue">conditions</font> or trends in the <font color="blue">regulatory</font> climate and the <font color="blue">biotechnology</font> and     <font color="blue">pharmaceutical</font> industries;                                         ●       changes in the <font color="blue">market valuations</font> of similar companies; and                                         ●       <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>In addition, equity markets in general, and the market for <font color="blue">biotechnology</font> and     <font color="blue">life sciences companies</font> in particular, have experienced <font color="blue">extreme price</font> and     <font color="blue">volume fluctuations</font> that have often been unrelated or <font color="blue">disproportionate</font> to     the operating performance of <font color="blue">companies traded</font> in those markets</td>
    </tr>
    <tr>
      <td>These broad     market and <font color="blue">industry factors may materially affect</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font>, regardless of our <font color="blue">development</font> and operating performance</td>
    </tr>
    <tr>
      <td>In     the past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a companyapstas     securities, securities class-action <font color="blue">litigation</font> has <font color="blue">often been instituted</font>     against that company</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font>, if instituted <font color="blue">against us</font>, could cause     us to incur substantial costs to <font color="blue">defend such</font> claims and divert <font color="blue">management</font>apstas     attention and resources, which could seriously harm our business</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________       Certain anti-takeover provisions in our <font color="blue">charter documents</font> and <font color="blue">Delaware </font>law     could make a third-party <font color="blue">acquisition</font> of us <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could limit</font> the     <font color="blue">price investors might</font> be willing to pay in the future for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and     bylaws could have the effect of making it more <font color="blue">difficult</font> for a <font color="blue">third party</font>     to acquire, or of <font color="blue">discouraging</font> a <font color="blue">third party</font> from attempting to acquire, or     <font color="blue">control us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> limit the price that <font color="blue">certain investors might</font>     be willing to pay in the future for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our amended     and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> allows us to <font color="blue">issue preferred stock</font>     <font color="blue">with rights senior</font> to those of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The issuance of preferred     stock  could  decrease the amount of earnings and <font color="blue">assets available</font> for     <font color="blue">distribution</font> to the holders of our <font color="blue">common stock</font> or could <font color="blue">adversely</font> affect     the rights and powers, including <font color="blue">voting rights</font>, of <font color="blue">such holders</font></td>
    </tr>
    <tr>
      <td>In certain     circumstances, such issuance could have the effect of <font color="blue">decreasing</font> the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our amended and <font color="blue">restated bylaws eliminate</font> the     right of <font color="blue">stockholders</font> to call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font>, which could     make it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to effect <font color="blue">certain corporate actions</font></td>
    </tr>
  </tbody>
</table>